Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) candidate from China's Simcere in a deal that would be worth up to €1.05 billion ...

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. The deal centers on SIM0709, which ...

The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory ...

Two recent studies from the University of California, Riverside, published in the same issue of Gut Microbes highlight the role of a gene called PTPN2 in protecting the gut from harmful bacteria ...

Caldera Therapeutics has burst onto the scene with $112.5 million in combined series A cash the Massachusetts biotech will use to fund development of an inflammatory bowel disease (IBD) drug licensed ...

2025 largely saw more of the same in the independent broker/dealer space, except for one big thing most advisors didn’t see coming: Commonwealth Financial Network’s sale to LPL Financial. LPL closed ...

The chronic and relapsing nature of inflammatory bowel disease (IBD) means patients must go to the doctor for ongoing monitoring to predict and prevent flares and check treatment effectiveness.

Women with inflammatory bowel disease (IBD) are 3 times more likely to forgo having children than people without the condition — it’s a trend driven by fear and confusion about what the disease would ...

Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the gastrointestinal disease: ulcerative colitis and Crohn’s disease. But one ...

Inflammatory bowel disease (IBD), which causes inflammation in the digestive tract, may complicate other health concerns as patients age. To address the specific challenges faced by older adults with ...

As IBD cases surge worldwide, scientists reveal how Western eating habits destabilise the gut–immune axis, and why tailored nutrition may be the key to stopping inflammation before it starts. Review: ...